首页> 美国卫生研究院文献>Systematic Reviews >Perioperative management of antiplatelet therapy in patients undergoing non-cardiac surgery following coronary stent placement: a systematic review
【2h】

Perioperative management of antiplatelet therapy in patients undergoing non-cardiac surgery following coronary stent placement: a systematic review

机译:冠状动脉支架置入术后非心脏手术患者的抗血小板治疗围手术期管理:系统评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundThe correct perioperative management of antiplatelet therapy (APT) in patients undergoing non-cardiac surgery (NCS) is often debated by clinicians. American College of Cardiology (ACC) and American Heart Association (AHA) guidelines recommend postponing elective NCS at least 3 months after stent implantation. Regardless of the timing of surgery, ACC/AHA guidelines recommend continuing at least ASA throughout the perioperative period and ideally continuing dual APT (DAPT) therapy “unless surgery demands discontinuation.” The objective of this review was to ascertain the risks and benefits of APT in the perioperative period, to assess how these risks and benefits vary by APT management, and the significance of length of time since stent implantation before operative intervention.
机译:背景技术临床医生经常对非心脏手术(NCS)患者的围手术期抗血小板治疗(APT)的正确处理进行辩论。美国心脏病学会(ACC)和美国心脏协会(AHA)指南建议将选择性NCS推迟至支架植入后至少3个月。无论手术时机如何,ACC / AHA指南建议在整个围手术期至少继续使用ASA,理想情况下建议继续进行双重APT(DAPT)治疗,“除非手术需要中止。”这篇综述的目的是确定围手术期APT的风险和益处,评估通过APT管理这些风险和益处如何变化,以及自从在进行手术干预之前植入支架以来的时间长度的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号